Ipsen Says Iqirvo Secured FDA Accelerated Approval As First-In-Class PPAR Treatment For Primary Biliary Cholangitis; Iqirvo Was In-licensed From GENFIT In 2021

Iqirvo is a first-in-class oral, once-daily peroxisome proliferator-activated receptor (PPAR) agonist. Iqirvo was in-licensed from GENFIT in 2021.

Iqirvo was discovered and developed by GENFIT and Ipsen licensed the exclusive worldwide rights (except China, Hong Kong, Taiwan and Macau) to elafibranor from GENFIT in 2021.